Addimmune, a clinical-stage gene and cell therapy company developing a functional cure for HIV, agreed to go public via a SPAC merger with 10x Capital Venture Acquisition, a special purpose acquisition company, and American Gene Technologies International, a gene and cell therapeutics company, in a $800m deal. “We’re at the forefront of gene therapy for HIV, working to transform the fear of a lifelong disease into hope for a single-administration, one-and-done cure. We believe that people living with HIV may no longer require lifelong treatment and we imagine a day when this disease no longer causes suffering or claims lives anywhere in the world. We’re excited about our collaboration with 10X. They bring a deep understanding of both the capital markets and the innovation that drives Addimmune. They will be a valuable partner to shepherd the combined company into the public market,” Jeff Galvin, American Gene Technologies International CEO.